Increased expression of urotensin II is associated with poor prognosis in hepatocellular carcinoma

Liu,Dian‑Gang; Chen,Jing; Wang,Hong‑Xia; Li,Bao‑Xin

doi:10.3892/ol.2016.5344

Increased expression of urotensin II is associated with poor prognosis in hepatocellular carcinoma

Authors:
- Dian‑Gang Liu
- Jing Chen
- Hong‑Xia Wang
- Bao‑Xin Li
View Affiliations

Affiliations: Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, P.R. China, Department of Gastroenterology, The Second Affiliated Hospital, Harbin Medical University, Harbin, Heilongjiang 150000, P.R. China, Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, P.R. China, Department of Pharmacology, Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China
Published online on: November 2, 2016 https://doi.org/10.3892/ol.2016.5344
Pages: 4961-4968
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Urotensin II (UII) and the urotensin II receptor (UT) exhibit mitogenic effects on tumor growth. Our previous study demonstrated that the UII/UT system is upregulated in hepatocellular carcinoma (HCC) and may enhance the proliferation of human hepatoma cells. However, the clinical significance of UII/UT expression in HCC remains unclear. The present study assessed UII messenger RNA (mRNA) expression in 129 surgical specimens obtained from HCC patients using reverse transcription quantitative‑polymerase chain reaction. The association between UII mRNA expression and clinicopathological parameters and overall survival rates was also investigated. The results revealed that UII and UT mRNA expression was significantly increased in HCC tissue compared with adjacent non‑cancerous liver tissue (P<0.001). Furthermore, a significant correlation was identified between UII expression and histological differentiation (P<0.01), tumor size (P<0.01) and tumor stage (P=0.026). Kaplan‑Meier survival analysis indicated that overall survival time was significantly shorter in patients with high UII expression, compared with those with low UII expression (P<0.001). Multivariate analyses indicated that UII expression was an independent predictor of overall survival (odds ratio, 1.12; P<0.001). In addition, UII mRNA was correlated with vascular endothelial growth factor mRNA expression. Therefore, UII expression is an independent biomarker for the prognosis of patients with HCC and thus, the UII/UT system may present a novel therapeutic target for the treatment of HCC.

View Figures

View References

1	Chow PK, Choo SP, Ng DC, Lo RH, Wang ML, Toh HC, Tai DW, Goh BK, Wong JS, Tay KH, et al: National cancer centre singapore consensus guidelines for hepatocellular carcinoma. Liver Cancer. 5:97–106. 2016. View Article : Google Scholar : PubMed/NCBI
2	Yang JD and Roberts LR: Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol. 7:448–458. 2010. View Article : Google Scholar : PubMed/NCBI
3	Maluccio M and Covey A: Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin. 62:394–399. 2012. View Article : Google Scholar : PubMed/NCBI
4	Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74:2913–2921. 2014. View Article : Google Scholar : PubMed/NCBI
5	Bodzin AS and Busuttil RW: Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome. World J Hepatol. 7:1157–1167. 2015. View Article : Google Scholar : PubMed/NCBI
6	Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
7	Bruix J and Sherman M: American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: An update. Hepatology. 53:1020–1022. 2011. View Article : Google Scholar : PubMed/NCBI
8	Llovet JM and Bruix J: Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 48:1312–1327. 2008. View Article : Google Scholar : PubMed/NCBI
9	Peck-Radosavljevic M: Drug therapy for advanced-stage liver cancer. Liver cancer. 3:125–131. 2014. View Article : Google Scholar : PubMed/NCBI
10	Albertin G, Guidolin D, Sorato E, Oselladore B, Tortorella C and Ribatti D: Urotensin-II-stimulated expression of pro-angiogenic factors in human vascular endothelial cells. Regul Pept. 172:16–22. 2011. View Article : Google Scholar : PubMed/NCBI
11	Yumrutas O, Oztuzcu S, Büyükhatipoglu H, Bozgeyik I, Bozgeyik E, Igci YZ, Bagis H, Cevik MO, Kalender ME, Eslik Z and Arslan A: The role of the UTS2 gene polymorphisms and plasma Urotensin-II levels in breast cancer. Tumor Bio. 36:4427–4432. 2015. View Article : Google Scholar
12	Franco R, Zappavigna S, Gigantino V, Luce A, Cantile M, Cerrone M, Facchini G, Perdonà S, Pignata S, Di Lorenzo G, et al: Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion. J Exp Clin Cancer Res. 33:482014. View Article : Google Scholar : PubMed/NCBI
13	Federico A, Zappavigna S, Romano M, Grieco P, Luce A, Marra M, Gravina AG, Stiuso P, D'Armiento FP, Vitale G, et al: Urotensin-II receptor is over-expressed in colon cancer cell lines and in colon carcinoma in humans. Eur J Clin Invest. 44:285–294. 2014. View Article : Google Scholar : PubMed/NCBI
14	Grieco P, Franco R, Bozzuto G, Toccacieli L, Sgambato A, Marra M, Zappavigna S, Migaldi M, Rossi G, Striano S, et al: Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells. J Cell Biochem. 112:341–353. 2011. View Article : Google Scholar : PubMed/NCBI
15	Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, et al: Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature. 401:282–286. 1999. View Article : Google Scholar : PubMed/NCBI
16	Takahashi K, Totsune K, Murakami O, Arihara Z, Noshiro T, Hayashi Y and Shibahara S: Expression of urotensin II and its receptor in adrenal tumors and stimulation of proliferation of cultured tumor cells by urotensin II. Peptides. 24:301–306. 2003. View Article : Google Scholar : PubMed/NCBI
17	Takahashi K, Totsune K, Murakami O and Shibahara S: Expression of urotensin II and urotensin II receptor mRNAs in various human tumor cell lines and secretion of urotensin II-like immunoreactivity by SW-13 adrenocortical carcinoma cells. Peptides. 22:1175–1179. 2001. View Article : Google Scholar : PubMed/NCBI
18	Wang H, Dong K, Xue X, Feng P and Wang X: Elevated expression of urotensin II and its receptor in diethylnitrosamine-mediated precancerous lesions in rat liver. Peptides. 32:382–387. 2011. View Article : Google Scholar : PubMed/NCBI
19	Liu D, Chen J, Wang J, Zhang Z, Ma X, Jia J and Wang Y: Increased expression of urotensin II and GPR14 in patients with cirrhosis and portal hypertension. Int J Mol Med. 25:845–851. 2010.PubMed/NCBI
20	Yu XT, Wang PY, Shi ZM, Dong K, Feng P, Wang HX and Wang XJ: Up-regulation of urotensin ii and its receptor contributes to human hepatocellular carcinoma growth via activation of the PKC, ERK1/2, and p38 MAPK signaling pathways. Molecules. 19:20768–20779. 2014. View Article : Google Scholar : PubMed/NCBI
21	Shariff MI, Cox IJ, Gomaa AI, Khan SA, Gedroyc W and Taylor-Robinson SD: Hepatocellular carcinoma: Current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol. 3:353–367. 2009. View Article : Google Scholar : PubMed/NCBI
22	Lei HJ, Chau GY, Lui WY, Tsay SH, King KL, Loong CC and Wu CW: Prognostic value and clinical relevance of the 6th Edition 2002 American joint committee on cancer staging system in patients with resectable hepatocellular carcinoma. J Am Coll Surg. 203:426–435. 2006. View Article : Google Scholar : PubMed/NCBI
23	Pirisi M, Leutner M, Pinato DJ, Avellini C, Carsana L, Toniutto P, Fabris C and Boldorini R: Reliability and reproducibility of the edmondson grading of hepatocellular carcinoma using paired core biopsy and surgical resection specimens. Arch Pathol Lab Med. 134:1818–1822. 2010.PubMed/NCBI
24	Wang SB, Wang JH, Chen J, Giri RK and Chen MH: Natural history of liver cirrhosis in south China based on a large cohort study in one center: A follow-up study for up to 5 years in 920 patients. Chin Med J (Engl). 125:2157–2162. 2012.PubMed/NCBI
25	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
27	Bagnato A and Catt KJ: Endothelins as autocrine regulators of tumor cell growth. Trends Endocrinol Metab. 9:378–383. 1998. View Article : Google Scholar : PubMed/NCBI
28	Zhou CH, Wan YY, Chu XH, Song Z, Xing SH, Wu YQ and Yin XX: Urotensin II contributes to the formation of lung adenocarcinoma inflammatory microenvironment through the NF-κB pathway in tumor-bearing nude mice. Oncol Lett. 4:1259–1263. 2012.PubMed/NCBI
29	Dai J and Rabie AB: VEGF: An essential mediator of both angiogenesis and endochondral ossification. J Dent Res. 86:937–950. 2007. View Article : Google Scholar : PubMed/NCBI
30	Shibuya M: Vascular endothelial growth factor and its receptor system: Physiological functions in angiogenesis and pathological roles in various diseases. J Biochem. 153:13–19. 2013. View Article : Google Scholar : PubMed/NCBI
31	Mukozu T, Nagai H, Matsui D, Kanekawa T and Sumino Y: Serum VEGF as a tumor marker in patients with HCV-related liver cirrhosis and hepatocellular carcinoma. Anticancer Res. 33:1013–1021. 2013.PubMed/NCBI
32	Marra M, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, Giudice A, Stiuso P, Abbruzzese A, Sperlongano R, Accardo M, et al: Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: An overview. J Transl Med. 9:1712011. View Article : Google Scholar : PubMed/NCBI
33	Colombino M, Sperlongano P, Izzo F, Tatangelo F, Botti G, Lombardi A, Accardo M, Tarantino L, Sordelli I, Agresti M, et al: BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy. Cell Death Dis. 3:e2592012. View Article : Google Scholar : PubMed/NCBI
34	Caraglia M, Giuberti G, Marra M, Addeo R, Montella L, Murolo M, Sperlongano P, Vincenzi B, Naviglio S, Prete SD, et al: Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. Cell Death Dis. 2:e1502011. View Article : Google Scholar : PubMed/NCBI
35	Scognamiglio PL, Di Natale C, Perretta G and Marasco D: From peptides to small molecules: An intriguing but intricated way to new drugs. Curr Med Chem. 20:3803–3817. 2013. View Article : Google Scholar : PubMed/NCBI